BioAdaptives Statistics
Total Valuation
BioAdaptives has a market cap or net worth of 363,262. The enterprise value is 495,891.
| Market Cap | 363,262 |
| Enterprise Value | 495,891 |
Important Dates
The next estimated earnings date is Friday, November 14, 2025.
| Earnings Date | Nov 14, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
BioAdaptives has 12.01 million shares outstanding. The number of shares has increased by 64.01% in one year.
| Current Share Class | 12.01M |
| Shares Outstanding | 12.01M |
| Shares Change (YoY) | +64.01% |
| Shares Change (QoQ) | +5.36% |
| Owned by Insiders (%) | 2.08% |
| Owned by Institutions (%) | n/a |
| Float | 11.76M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 112.85 |
| PB Ratio | -0.32 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -0.65 |
| EV / Sales | 154.05 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -1.29 |
Financial Position
The company has a current ratio of 0.18
| Current Ratio | 0.18 |
| Quick Ratio | 0.15 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.89 |
| Interest Coverage | -25.53 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -438.95% |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | 86.99% |
| Revenue Per Employee | 3,219 |
| Profits Per Employee | -764,487 |
| Employee Count | 1 |
| Asset Turnover | 0.02 |
| Inventory Turnover | 2.73 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -91.74% in the last 52 weeks. The beta is 0.93, so BioAdaptives's price volatility has been similar to the market average.
| Beta (5Y) | 0.93 |
| 52-Week Price Change | -91.74% |
| 50-Day Moving Average | 0.03 |
| 200-Day Moving Average | 0.07 |
| Relative Strength Index (RSI) | 48.08 |
| Average Volume (20 Days) | 222,291 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.11 |
Income Statement
In the last 12 months, BioAdaptives had revenue of 3,219 and -764,487 in losses. Loss per share was -0.07.
| Revenue | 3,219 |
| Gross Profit | -58,937 |
| Operating Income | -987,647 |
| Pretax Income | -764,487 |
| Net Income | -764,487 |
| EBITDA | -986,647 |
| EBIT | -987,647 |
| Loss Per Share | -0.07 |
Balance Sheet
The company has 210,582 in cash and 343,096 in debt, giving a net cash position of -132,514 or -0.01 per share.
| Cash & Cash Equivalents | 210,582 |
| Total Debt | 343,096 |
| Net Cash | -132,514 |
| Net Cash Per Share | -0.01 |
| Equity (Book Value) | -1.14M |
| Book Value Per Share | -0.11 |
| Working Capital | -1.15M |
Cash Flow
In the last 12 months, operating cash flow was -365,768 and capital expenditures -18,000, giving a free cash flow of -383,768.
| Operating Cash Flow | -365,768 |
| Capital Expenditures | -18,000 |
| Free Cash Flow | -383,768 |
| FCF Per Share | -0.03 |
Margins
| Gross Margin | n/a |
| Operating Margin | -30,681.80% |
| Pretax Margin | -23,749.21% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
BioAdaptives does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -64.01% |
| Shareholder Yield | -64.01% |
| Earnings Yield | -210.45% |
| FCF Yield | -105.64% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on January 23, 2025. It was a forward split with a ratio of 2.
| Last Split Date | Jan 23, 2025 |
| Split Type | Forward |
| Split Ratio | 2 |
Scores
BioAdaptives has an Altman Z-Score of -65.63 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -65.63 |
| Piotroski F-Score | 2 |